Characterization of neuroinflammatory positron emission tomography biomarkers in chronic traumatic encephalopathy

Cassis Varlow,1,2 Ashley C. Knight,1,2 Paul McQuade3 and Neil Vasdev1,2

Chronic traumatic encephalopathy is a neurological disorder associated with head trauma and is confirmed upon autopsy. PET imaging of chronic traumatic encephalopathy may provide a means to move towards ante-mortem diagnosis and therapeutic intervention following brain injuries. Characterization of the neuroinflammatory PET biomarkers, 18 kDa translocator protein and monoamine oxidase-B was conducted using [3H]PBR-28 and [3H]L-deprenyl, respectively, in post-mortem chronic traumatic encephalopathy brain tissue. [3H]PBR-28 displayed high specific binding in both chronic traumatic encephalopathy (95.40 ± 1.87%; n = 11 cases) and healthy controls (89.89 ± 8.52%, n = 3 cases). Cell-type expression of the 18 kDa translocator protein was confirmed by immunofluorescence to microglia, astrocyte and macrophage markers. [3H]L-deprenyl also displayed high specific binding in chronic traumatic encephalopathy (96.95 ± 1.43%; n = 12 cases) and healthy controls (93.24 ± 0.43%; n = 2 cases), with the distribution co-localized to astrocytes by immunofluorescence. Saturation analysis was performed to quantify the target density of the 18 kDa translocator protein and monoamine oxidase-B in both chronic traumatic encephalopathy and healthy control tissue. Using [3H]PBR-28, the target density of the 18 kDa translocator protein in healthy controls was 177.91 ± 56.96 nM (n = 7 cases; mean ± standard deviation); however, a highly variable target density (345.84 ± 372.42 nM; n = 11 cases; mean ± standard deviation) was measured in chronic traumatic encephalopathy. [3H]L-deprenyl quantified a monoamine oxidase-B target density of 304.23 ± 115.93 nM (n = 8 cases; mean ± standard deviation) in healthy control tissue and is similar to the target density in chronic traumatic encephalopathy tissues (365.80 ± 128.55 nM; n = 12 cases; mean ± standard deviation). A two-sample t-test determined no significant difference in the target density values of the 18 kDa translocator protein and monoamine oxidase-B between healthy controls and chronic traumatic encephalopathy (P > 0.05), albeit a trend towards increased expression of both targets was observed in chronic traumatic encephalopathy. To our knowledge, this work represents the first in vitro characterization of 18 kDa translocator protein and monoamine oxidase-B in chronic traumatic encephalopathy and reveals the variability in neuroinflammatory pathology following brain injuries. These preliminary findings will be considered when designing PET imaging studies after brain injury and for the ultimate goal of imaging chronic traumatic encephalopathy in vivo.

1 Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada M5T 1R8
2 Institute of Medical Science, University of Toronto, Toronto, ON, Canada M5S 1A8
3 Takeda Pharmaceutical Company, Cambridge, MA 02139, USA

Correspondence to: Neil Vasdev
CAMH, 250 College St, Room PET G11
Toronto, ON Canada M5T 1R8
E-mail: neil.vasdev@utoronto.ca

Keywords: chronic traumatic encephalopathy; neuroinflammation; PET imaging; TSPO; MAO-B

Abbreviations: CTE = chronic traumatic encephalopathy; CSF-1R = colony stimulating factor receptor 1; HC = healthy control; MAO-B = monoamine oxidase-B; NFL = National Football League; ROS = reactive oxygen species; SNP = single-nucleotide
Introduction

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with sustained repetitive head injuries. Those at risk for developing CTE include contact sport athletes, military veterans and victims of domestic violence.1 Although neurodegeneration can be classified in the clinic by cognitive or behavioural presentations, diagnosis of CTE can only be determined upon post-mortem neuropathological evaluation during autopsy. Diagnosis of CTE is generally based on the perivascular accumulation of hyperphosphorylated tau protein,2,3 although the 2014 traumatic encephalopathy syndrome (TES) criteria have been proposed to diagnose CTE in vivo.4 Revisions of the TES criteria to include cognitive symptoms and application of biomarkers for Alzheimer’s disease-tau including 

\[ ^{18}\text{F}]\text{FDDNP}, \quad \left[ ^{11}\text{C}\right]\text{R}-\text{PK11195} \]

is the first-generation radiopharmaceutical for PET imaging of TSPO; however, its limitations include low signal-to-noise and brain penetration, as well as high blood protein binding.26,27 Second- and third-generation TSPO-PET radiopharmaceuticals were subsequently developed, including \[ ^{18}\text{F}]\text{FEPPA}, \quad \left[ ^{11}\text{C}\right]\text{PBR-28}, \quad \left[ ^{18}\text{F}\right]\text{PBR-06}, \quad \left[ ^{11}\text{C}\right]\text{DPA-713}, \quad \left[ ^{18}\text{F}\right]\text{GE180} \]

and \[ ^{11}\text{C}]\text{ER176} . \]

PET imaging of TSPO has been conducted in individuals who have sustained TBIs to evaluate short- and long-term neuroinflammation associated with head injuries. In former National Football League (NFL) players, who are considered ‘at-risk’ of developing CTE, a significant increase in total distribution volume (\( V_T \)) of \[ ^{11}\text{C}]\text{DPA-713} \] to TSPO in 12 brain regions was observed compared with age-matched, healthy controls (HCs).28 In a subsequent study using \[ ^{11}\text{C}]\text{DPA-713} \], active or former NFL players showed higher \( V_T \) by regional analysis compared with HCs.22 However, TSPO expression is not exclusive to reactive microglia but is expressed on reactive astrocytes, endothelial cells and central nervous system infiltrating macrophages and monocytes.29 There is also high variability in non-displaceable binding across patient populations that needs to be considered for designing and interpreting TSPO-PET studies.30

Another short-coming of TSPO-PET is the sensitivity of second-generation radiotracers to the TSPO single-polymerism; TSPO = translocator protein-18 kDa; TES = traumatic encephalopathy syndrome; TBI = traumatic brain injury; TBS = Tris–HCl buffered saline
nucleotide polymorphism (SNP), rs6971, resulting in low-, mixed- and high-affinity binders which requires genetic profiling before imaging with these radiopharmaceuticals.

Alternative biomarkers beyond TSPO are avidly sought to develop PET tracers targeting markers of specific cell types involved in neuroinflammation.39-32 Monoamine oxidase-B (MAO-B) has been explored as a PET neuroinflammatory biomarker using [11C]L-deprenyl-D2,33 as this target is primarily expressed on astrocytes as revealed by microautoradiography with [3H]L-deprenyl.34 Furthermore, in the spinal cord from patients diagnosed with motor neuron disease, MAO-B expression co-localized to reactive astrocytes labelled for glial fibrillary acidic protein (GFAP), a selective astrocyte marker. Increased astrocytic MAO-B activity due to astrogliosis observed in the brains of patients with Alzheimer’s disease may impart oxidative stress through catalytic reactive oxygen species (ROS) generation.35-37 Therefore, MAO-B inhibition has been proposed as neuroprotective in diseases, where ROS generation is implicated in neurodegeneration and continues to be investigated.38

Our laboratories and others conduct in vivo PET imaging studies for pre-clinical and clinical research of TSPO and MAO-B availability to study brain health illnesses including neuroinflammation.25,39-44 In the present study, in vitro radioligand binding methods were employed to evaluate [3H]PBR-28 for TSPO and [3H]L-deprenyl for MAO-B to image neuroinflammatory targets in pathologically diagnosed cases of human CTE brains compared with HCs. [3H]PBR-28 and [3H]L-deprenyl demonstrated optimal specific binding by autoradiography (ARG) and were further characterized for distribution in CTE and validated with immunostaining. Saturation analysis in homogenate tissue was performed to evaluate differences in TSPO and MAO-B target density (B_max) between CTE and HCs. We hypothesize that these experiments will guide in vivo PET imaging studies of neuroinflammation in individuals following TBIs.

### Table 1 Demographic data

| Case ID/PIN | Primary pathological diagnosis | Sex | Age |
|-------------|--------------------------------|-----|-----|
| CTE(1)      | CTE I                          | M   | 30  |
| CTE(2)      | CTE I                          | M   | 46  |
| CTE(3)      | CTE I                          | M   | 60  |
| CTE(4)      | CTE II                         | M   | 46  |
| CTE(5)      | CTE II                         | M   | 84  |
| CTE(6)      | CTE II                         | M   | 46  |
| CTE(7)      | CTE IV                         | M   | 75  |
| CTE(8)      | CTE IV                         | M   | 74  |
| CTE(9)      | CTE IV                         | M   | 87  |
| CTE(10)     | CTE IV                         | M   | 78  |
| CTE(11)     | CTE IV                         | M   | 71  |
| CTE(12)     | CTE IV                         | M   | 87  |

### Materials and methods

#### General

Radiolabelled PBR-28 ([3H]PBR-28; 82.0 Ci/mmol (3.03 TBq/mmol), 1.0 mCi/ml (37 MBq/ml)), L-deprenyl ([3H]L-deprenyl; 82.0 Ci/mmol, 1.0 mCi/ml), CPPC ([3H]CPPC; 79.0 Ci/mmol, 1.0 mCi/ml) and SMW-139 ([3H]SMW-139; 82.0 Ci/mmol, 1.0 mCi/ml) were purchased commercially (Novandi Chemistry AB Södertälje, Sweden). Lazabemide hydrochloride (BioTechne, MN, USA) was obtained commercially. All other reagents were purchased from Millipore Sigma unless otherwise stated.

#### Human post-mortem brain tissue

Fresh-frozen human CTE and HC brain tissues were obtained from the Boston University-Veteran’s Affairs-Concussion Legacy Foundation Brain Bank, Target ALS Post-mortem Tissue Core and Tissue Solutions in accordance with the guidelines put forth by the Centre for Addiction and Mental Health Research Ethics Board (protocol #036-2019). Tissue demographics are summarized in Table 1.

#### Genotyping

DNA extraction was performed on all tissue samples (QIAamp DNA Micro Kit, Qiagen) to genotype the rs6971 SNP within the TSPO gene. Genotyping was performed by Agena Mass Array at the Centre for Applied Genomics (The Hospital for Sick Children, Toronto, ON, Canada) to exclude low-affinity binders with Thr/Thr Ala147Thr polymorphism.

#### Homogenate preparation

Fresh-frozen human post-mortem CTE (Brodmann area 8/9; superior frontal cortex) and HC (frontal cortex) brain tissues were homogenized to a concentration of 100 mg/ml (wet weight). Tissues were mechanically homogenized on ice in ice-cold 50 mM Tris–HCl buffered saline (TBS) (pH 7.4) using a dounce homogenizer (Fisher Scientific). Homogenates were snap frozen and stored at −80°C.

#### Saturation analysis

Saturation analysis of [3H]PBR-28 and [3H]L-deprenyl in brain homogenates for determination of target affinity (K_d) and B_max was performed with modifications to previously described protocols.45,46 Briefly, frozen aliquots (−80°C) of homogenized (100 mg/ml in Tris-buffered saline, pH 7.4) healthy human brain, or CTE human brain were thawed and diluted 0.25 mg/ml. To define non-specific binding of
each $[^3]H$PBR-28 and $[^3]H$L-deprenyl, unlabelled PK-11195 and lazabemide hydrochloride, respectively, [10 mM in dimethyl sulfoxide (DMSO)], were diluted to 100 µM with assay buffer to yield <1% DMSO/buffer. DMSO concentration was maintained across reactions. Concentrations of $[^3]H$PBR-28 and $[^3]H$L-deprenyl were increased from ~0.05 nM to a concentration of at least 10-fold the reported $K_I$ values.47,48 Unlabelled PK-11195 and lazabemide hydrochloride for each $[^3]H$PBR-28 and $[^3]H$L-deprenyl, respectively, were added to a final concentration of 10 µM within the assay. Reactions were initiated by the addition of brain homogenate to achieve a final concentration of 25 µg tissue/reaction in a final assay volume of 1000 µL. Protein concentration was confirmed by Bradford assay (Millipore Sigma) and used to normalize saturation analysis. After incubation for 60 min at room temperature, reactions were terminated by filtration over a Whatman GF/B glass fibre filtermat pre-treated with 0.03% polyethylenimine using a Brandel cell harvester (Gaithersburg, MD) and rapidly washed three times with 2 ml ice-cold saline. The filters were soaked in 2 ml scintillation cocktail for 4 h prior to scintillation counting (Tricarb 5110TR scintillation counter; Perkin Elmer). All assays were performed at least in duplicate.

**Autoradiography**

Fresh-frozen brains were cryosectioned (Leica CM3050S; 10 µm), thaw-mounted on glass slides (Fisher Superfrost Plus Gold) and stored at −80°C for later use. $[^3]H$PBR-28 ARG was carried out to evaluate specific binding, where tissues were incubated with 3 nM $[^3]H$PBR-28 with a 10 µM unlabelled PK-11195 or a vehicle in 50 mM Tris/0.9% NaCl pH 7.4 for 1 h at room temperature. $[^3]H$L-deprenyl ARG was carried out to evaluate specific binding, where tissues were incubated with 4 nM $[^3]H$L-deprenyl with a 10 µM unlabelled lazabemide hydrochloride or a vehicle in PBS + 0.1% BSA for 1 h at room temperature. Tissue sections were subsequently washed with saline (2 × 5 min, 4°C) and deionized water (1 × 10 s, 4°C). Slides were air-dried and exposed to phosphor screens (BAS-IP TR4020; GE Healthcare) for 4 days with a full range tritium standard to permit quantification of radioligand binding (American Radiolabeled Chemicals, Inc.; St Louis, MO). Images were generated by scanning with an Amersham Typhoon phosphorimager (GE Healthcare). Region of interest (ROI) analysis was performed using MCID 7.0 imaging suite (Interfocus Imaging, Cambridge, UK). Raw nanocurie/milligram (nCi/mg), per cent specific binding (% specific binding = [(total signal – non-specific signal)/(total signal)] × 100) is reported.

**Immunohistochemistry**

Fresh-frozen human brain tissues were acclimated to room temperature and then exposed to post-fixation by 4% paraformaldehyde. Following a 10 min wash in buffer (TBS containing 0.1% Triton-X), tissues were exposed to protein block (5% goat serum, 0.1% Triton-X-100, 1% BSA; in TBS). Tissues were incubated with rabbit anti-PBR (ab109497; Abcam, Cambridge, MA). After washing, sections were incubated with a rabbit-on-rodent polymer (Vector Laboratories, 30 min) secondary antibody and detected with 3,3′-diaminobenzidine development. Sections were counter-stained with haemotoxylin, dehydrated and coverslipped. Slides were imaged using an Olympus VS200 (Olympus Corporation).

**Immunofluorescence**

Fresh-frozen human brain tissues were acclimated to room temperature and then exposed to post-fixation by 4% paraformaldehyde. Following a 10 min wash in buffer (TBS containing 0.1% Triton-X), tissues were exposed to protein block (5% goat serum, 0.1% Triton-X-100, 1% BSA; in TBS). Tissues were incubated with rabbit anti-PBR (ab109497; Abcam, Cambridge, MA), and one of the following: mouse anti-Iba1 (GT10312; Invitrogen, 1:500), mouse anti-CD68 (M0814; Agilent, 1:500), mouse anti-GFAP (G3898; Millipore Sigma, 1:500) or antibody diluted overnight at 4°C and then washed with TBS buffer 3 × 5 min. For detection, sections were incubated with a goat anti-rabbit secondary antibody conjugated to Alexa-Fluor-568 (Invitrogen) and a goat anti-mouse secondary antibody conjugated to Alexa-Fluor-488 (Invitrogen) at room temperature for 60 min. Following washing and 10 min incubation with DAPI, slides were washed with distilled water and coverslipped. Slides were imaged using an Olympus VS200 (Olympus Corporation).

**Statistical analysis**

Statistical analyses were performed in GraphPad Prism 8 (San Diego, CA, USA). Statistical significance was evaluated using a two-tailed Student’s $t$-test. No statistical methods were used to predetermine sample size. The sample size was determined by tissue availability.

**Data availability**

Data that support the findings of this study are available from the corresponding author upon reasonable request.

**Results**

**Specific binding of neuroinflammatory radiotracers in human post-mortem tissue**

Initially, we evaluated the tritium-labelled PET tracers $[^3]H$PBR-28 and $[^3]H$L-deprenyl for TSPO and MAO-B, respectively, and two putative radiotracers/targets for neuroinflammation, namely, $[^3]H$CPPC for colony stimulating factor receptor 1 (CSF-1R) and $[^3]H$SMW-139 for purinergic
receptor 7 receptors. Thin section ARG was performed to evaluate the specific signal of all four radiotracers for their respective neuroinflammatory targets. With previously reported conditions,49 [3H]SMW-139 at 15 nM displayed negligible signal in fresh-frozen human post-mortem CTE tissues (n = 4; data not shown). [3H]CPPC was similarly assayed at 10 nM utilizing previous conditions.50,51 Although radiotracer binding was observed in post-mortem CTE tissues, it was not specific as defined by homologous blockade (15.34 ± 8.12%; n = 4). Because our preliminary ARG studies with [3H]SMW-139 and [3H]CPPC in CTE tissues showed little-to-no specific binding, these radiotracers were not evaluated further. High specific binding was observed with [3H]PBR-28 (3 nM) in both CTE (95.40 ± 1.87%; n = 11) and HC (89.89 ± 8.52%, n = 3) tissues. High specific binding was also observed with [3H]L-deprenyl (4 nM) in both CTE (96.95 ± 1.43%; n = 12) and HC (93.24 ± 0.43%; n = 2) tissues.

Distribution of TSPO: [3H]PBR-28 ARG and TSPO immunostaining and immunofluorescence

To characterize [3H]PBR-28 distribution in CTE and HC tissues, ARG was performed at a 3 nM radioligand concentration and whole section images were validated by immunohistochemistry with an anti-TSPO antibody (Fig. 1). The ARG signal aligned well with the immunostaining signal, where elevated radiotracer corresponded to areas of more dense antibody staining.

Dual immunofluorescent staining was utilized to show co-localization of TSPO positive cells with cell-type selective antibodies. Iba1 positive staining was observed in CTE tissue (Fig. 2A), along with TSPO positive staining (Fig. 2B). Co-localization of the Iba1 and TSPO signal was also observed, indicating microglial expression of TSPO in CTE (Fig. 2C). In HC tissue, there was little-to-no Iba1 positive signal by immunofluorescence (Fig. 2D); however, there was a positive TSPO signal (Fig. 2E). Co-localization of Iba1 to TSPO is likely attributed to blood-vessel staining, rather than microglial localization of TSPO (Fig. 2F).

Dual immunofluorescent staining was performed with antibodies to TSPO and the astrocytic marker, GFAP, to investigate TSPO expression on astrocytes. GFAP immunoreactive cells were identified in CTE tissue (Fig. 3A) along with TSPO immunoreactive cells (Fig. 3B) and merging the two stains displayed co-localization of TSPO to astrocytes in CTE (Fig. 3C). In HC tissue, immunoreactive GFAP cells were identified (Fig. 3D) alongside TSPO immunoreactive cells (Fig. 3E) and co-localization of the TSPO signal to GFAP expressing astrocytes was observed upon merging the stains (Fig. 3F).

The last cell-type investigated for TSPO expression was CD68 expressing macrophages and activated microglia. CD68 immunoreactive cells were observed in CTE and HC tissue (Fig. 4A) alongside TSPO immunoreactive cells (Fig. 4B) and co-localization were observed upon merged staining to indicate TSPO expression on CD68 immunoreactive cells. It is of note, however, there is a large cell population of CD68 expressing cells that do not express TSPO.

Distribution of MAO-B: [3H]L-deprenyl ARG and GFAP immunostaining

[3H]L-deprenyl distribution in CTE and HC tissues was demonstrated by ARG at 4 nM radioligand concentration, and whole section images were evaluated by immunofluorescence with an anti-GFAP antibody to show radiotracer signal corresponding to astrocyte expression (Fig. 5). [3H]L-deprenyl ARG signal again aligned well with the immunostaining signal, where elevated radiotracer corresponded to areas of more dense antibody staining.
Saturation binding assays were conducted to investigate changes in expression of TSPO and MAO-B in CTE compared with HC. Increasing concentrations of \(^{3}H\)PBR-28 (0.1–100 nM) allowed for saturability of the target and a quantification of the \(B_{\text{max}}\). Representative saturation curves are shown for each HC and CTE tissue samples (Fig. 6A). The TSPO \(B_{\text{max}}\) experimentally determined in HC tissue samples was 177.91 ± 56.96 nM \([n = 7\text{ cases};\text{mean} \pm \text{standard deviation (SD)}]\) compared with the \(B_{\text{max}}\) in CTE of...
345.84 ± 372.42 nM (n = 11 cases; mean ± SD; Fig. 6B). A two-sample t-test was performed to determine significance of the differences in $B_{\text{max}}$ between the HC and CTE and no significance was found ($P = 0.3399, t = 0.9838$).

To investigate differences in the density of MAO-B in CTE compared with HC, increasing concentrations of $[^3H]$L-deprenyl (0.1–75 nM) were incubated with tissue homogenates from HC or CTE samples, and representative saturation curves are shown in Fig. 6C. The MAO-B $B_{\text{max}}$ was 304.23 ± 115.93 nM (n = 8 cases; mean ± SD) in HC tissue compared with 365.80 ± 128.55 nM (n = 12 cases; mean ± SD) in CTE tissue (Fig. 6D). To determine if there was a significant difference in $B_{\text{max}}$ values between HC and CTE, a two-sample t-test was performed, and no significance was found ($P = 0.2903, t = 1.090$).

**Discussion**

**Specific binding of neuroinflammatory targeting radiotracers in human post-mortem tissue**

One of the challenges associated with CTE research is the widespread neuropathology across multiple brain regions as the disease progresses. Tau lesion formation originates...
in the frontal cortex and increases in size and spreads in later CTE stages and was therefore chosen as the ROI for this study. TSPO expression has been identified on microglia, macrophages, astrocytes, endothelial cells and neurons and is considered to be upregulated under a variety of neuroinflammatory conditions including stimulus and disease. It has been further hypothesized that upregulation of TSPO under inflammatory conditions is attributed to the expression on activated or pro-inflammatory microglial cells, although there is contrary evidence for its downregulation on activated macrophages. MAO-B is primarily expressed on astrocytes in the brain as shown through colocalization to GFAP positive cells by immunostaining. PET imaging studies have shown increased MAO-B and is attributed to astrogliosis in the brains of Alzheimer’s disease patients and is attributed to astrogliosis, albeit increased MAO-B availability has also been observed in normal ageing. 

[3H]PBR-28 and [3H]L-deprenyl were chosen as tool radioligands for the present work as they have been extensively characterized in vitro, for imaging MAO-B and TSPO, respectively. ARG was performed herein to establish in vitro signal-to-noise within the HC and CTE tissues for TSPO and MAO-B. Both [3H]PBR-28 and [3H]L-deprenyl displayed high specific binding in CTE and HC as expected. The high specific binding observed indicated that the present assay conditions were suitable for further target characterization.

**Distribution of TSPO: [3H]PBR-28 ARG and TSPO immunostaining and immunofluorescence**

[3H]PBR-28 was used to establish the localization of inflammatory cells in human post-mortem CTE tissues. TSPO immunohistochemistry was performed to support
the distribution of $[^3]H$PBR-28 within the tissue sections. ARG studies with $[^3]H$PBR-28 showed robust and reproducible specific binding that was preferentially localized to the grey matter, aligning with TSPO immunostaining. The high specific binding demonstrated with $[^3]H$PBR-28 allowed for further characterization of TSPO target density in CTE as well as exploring cell-type expression. As TSPO is not localized to a single cell-type, further immunostaining was performed to co-localize TSPO positive cells with cell-type-specific immunohistochemical markers. Dual immunofluorescent staining was utilized to show TSPO cell-type expression. In CTE tissue, co-localization of Iba1 and TSPO positive signal was observed, indicating microglial expression of TSPO in CTE. However, in HC tissue, there was little-to-no Iba1 positive signal by immunofluorescence in ROIs where there was a positive TSPO signal. Co-localization of Iba1 to TSPO appeared to be attributed to blood-vessel staining, rather than microglial localization of TSPO, and is not unexpected as TSPO is expressed on endothelial cells. Astrocytic TSPO expression was evaluated by dual TSPO/GFAP staining where co-localized signal was observed in both CTE and HC tissues. Macrophage and activated microglial TSPO expression were evaluated by dual TSPO/CD68 staining with co-localized signal in both CTE and HC tissues.

Although there was TSPO localization to Iba1, GFAP and CD68 positive cells in CTE, there was a prevalent population of TSPO-/Iba1+, TSPO-/GFAP+ and TSPO-/CD68+ cells in each of the samples. This may be attributed to differences in TSPO expression regionally throughout the brain, where the cellular origin of TSPO signal appears to depend on the brain region examined. TSPO signal in the hippocampus reportedly arises from microglia and astrocytes, whereas microglia, macrophages and astrocytes are the main contributors in the substantia nigra. In this work, evaluation was exclusive to the frontal cortex which may have characteristically unique TSPO cellular origin. These immunostaining studies show that it is imperative to investigate TSPO expression in human tissue acquired from diseased patients compared with controls. Stages of disease progression for CTE represent another variable as neuroinflammatory responses are not uniform, and is consistent with chronic neurodegenerative disease and psychiatric disorders. The varying cell-type expression of TSPO in CTE demonstrated herein by immunostaining suggests that the contribution of microglia, astrocytes and peripheral infiltrated macrophages all need to be considered when assessing neuroinflammation in CTE with TSPO-PET radiotracers.

**Distribution of MAO-B: $[^3]H$L-deprenyl ARG and GFAP immunostaining**

Upregulation of MAO-B is a marker of reactive astrocytes and is more cell-type selective than TSPO, suggesting the potential for measuring alteration in MAO-B-PET levels as a marker of astrocytosis in diseases such as Alzheimer’s disease and related dementias. In CTE, mRNA transcripts associated with neuroinflammation were elevated in CTE astrocyte groups compared with HCs, suggesting that white matter alterations are a critical aspect of CTE neurodegeneration. Herein, $[^3]H$L-deprenyl was used to establish the localization of astrocytic cells in human post-mortem CTE tissues. GFAP immunohistochemistry was performed as MAO-B expression is primarily attributed to astrocytes. $[^3]H$L-deprenyl ARG showed high specific binding that was preferentially localized to the grey matter which aligned with GFAP immunostaining. The high specific binding observed with $[^3]H$L-deprenyl allowed for further characterization of MAO-B target density in CTE.

**Quantification of TSPO and MAO-B target density in CTE and HC frontal cortex**

Saturation analysis was carried out to quantify the $B_{\text{max}}$ of TSPO and MAO-B in various stages of CTE frontal cortex compared with HCs. For $B_{\text{max}}$ quantification, all CTE samples were grouped together to get a single representative value from a larger number of cases rather than several values from smaller subgroups of each CTE stage evaluated. Saturation analysis with $[^3]H$PBR-28 quantified a $B_{\text{max}}$ for TSPO that was elevated in CTE compared with HC. Due to high variability within the CTE samples, the difference in $B_{\text{max}}$ was not significant. Interpretation of the TSPO $B_{\text{max}}$ followed clinical practice to include both mixed- and high-affinity binders; however, upon a Grubb’s test to identify outliers within the CTE samples, one mixed-affinity case was identified ($\alpha = 0.05$). This value was not excluded as the high variability in pathology is characteristic of CTE but should be noted upon interpretation of the data. TSPO expression has been reportedly regulated by a variety of factors including immune cell activation state, neuronal activity and ROIs studied. The inconsistencies with TSPO expression between neuroinflammatory conditions contribute to the need for additional neuroinflammation imaging targets with higher specificity than TSPO towards CTE. $[^3]H$L-deprenyl quantified the MAO-B $B_{\text{max}}$ of $304.23 \pm 115.93$ nM ($n = 8$ cases; mean ± SD) in HC tissue and is similar to the $B_{\text{max}}$ in CTE tissues ($365.80 \pm 128.35$ nM; $n = 12$ cases; mean ± SD). A two-sample $t$-test determined no significance in $B_{\text{max}}$ values between HC and CTE for TSPO ($P = 0.3399$, $t = 0.9838$) or MAO-B ($P = 0.2903$, $t = 1.090$). With a recent focus on quantification of astrocytosis in CTE, we measured differences in expression of MAO-B. Saturation analysis with $[^3]H$L-deprenyl quantified the MAO-B $B_{\text{max}}$ in HC tissue similar to the $B_{\text{max}}$ in CTE tissues and was not significantly different. There was high variability in MAO-B $B_{\text{max}}$ within the CTE and HC groups; however, expression of these targets can be impacted by unreported injuries and medications which may contribute to...
the differences in MAO-B expression observed within the HCs. In addition, no positive correlation between TSPO and MAO-B $B_{\text{max}}$ values was observed by Pearson correlation ($r = -0.237$, 95% confidence interval from $-0.7640$ to $0.4428$, $R^2 = 0.066$, $P = 0.470$). Although no significance in $B_{\text{max}}$ values of TSPO or MAO-B was determined, a trend towards increased TSPO and MAO-B expression was observed in CTE compared with HC.

These findings reveal the variability in pathology of TBIs and challenges associated with the evaluation of CTE and TBI using PET biomarkers for neuroinflammation. Further evaluation of TSPO and MAO-B in CTE is warranted to design PET imaging studies after brain injury and towards the goal of in vivo imaging studies of CTE. Further work to explore TSPO and MAO-B expression of CTE in larger sample sizes is needed as post-mortem evaluation of human CTE tissue is required in the absence of representative and reliable animal models. A larger sample size would allow further interpretation of subgroups by genotype and CTE stages. It would also be of value to include additional brain regions for analysis in future studies to explore neuroinflammatory pathology beyond the frontal cortex. While animal models of TBI are used for pre-clinical head injury research, there are caveats with reproducibility and clinical relevance to injuries sustained by humans. Variability in neuroinflammation is expected within CTE as there are many factors to consider in terms of the type of head injuries sustained, the frequency of the injuries, primary anatomical region of impact, duration of sustaining injury, sub-concussive impacts, etc. These factors are being investigated, particularly within current and retired NFL players, and provide opportunities to understand how head injuries contribute to CTE disease pathology and progression.

**Conclusion**

To our knowledge, this work represents the first in vitro evaluations of PET biomarkers for neuroinflammation in post-mortem CTE tissue and highlights the variability in neuroinflammatory pathology of brain injuries. PET imaging of patients after TBI in dual tracer paradigms could be used to quantify TSPO and MAO-B and shows promise for achieving the ultimate goal of imaging CTE in the living human brain.

**Acknowledgements**

The authors acknowledge the many families who contributed to this work and that tissue was obtained from the Boston University Alzheimer’s Disease Research and CTE Center’s brain bank, also referred to as the Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) or Veterans Affairs-Boston University-Concussion Legacy Foundation (VA-BU-CLF) brain bank (funded by grants P30AG072978, U54NS115266, R01AG062348 and RFIAG057902). Institutional Review Board approval for brain donation was obtained from the Boston University School of Medicine. The authors would also like to acknowledge the healthy control tissue was provided by Dr Brent Harris and the Georgetown University Postmortem Tissue Core who received funding from Target ALS to facilitate ALS bio-banking and ALS research. The authors would like to thank Dr Wai Haung (Ho) Yu and Dr Christopher Morrone for helpful discussions.

**Funding**

N.V. thanks the Azrieli Foundation, Canada Foundation for Innovation, Ontario Research Fund, the Canada Research Chairs Program and Takeda Pharmaceutical Company for support. C.V. thanks the Canadian Institutes of Health Research (CIHR) for the receipt of the Canada Graduate Scholarship (Doctoral).

**Competing interests**

N.V. is a co-founder of MedChem Imaging, Inc. A.C.K. and P.M. are employed by Takeda Pharmaceutical Company. All authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.

**References**

1. Banks SJ. Chronic traumatic encephalopathy (CTE). In: Tousi B and Cummings J, eds. Neuro-geriatrics: A clinical manual. Springer International Publishing; 2017:183–194.
2. McKee AC, Cairns NJ, Dickson DW, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2015;131:75–86.
3. Bieniek KF, Cairns NJ, Cravy JF, et al. The second NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2021;80(3):210–219.
4. Montenigro PH, Baugh CM, Daneshvar DH, et al. Clinical subtypes of chronic traumatic encephalopathy: Literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimer’s Res Ther. 2014;6(68):1–17.
5. Omalu B, Hammers J. Letter: Recommendation to create new neuropathologic guidelines for the post-mortem diagnosis of chronic traumatic encephalopathy. Neurosurgery. 2021;89(1):E97–E98.
6. Mez J, Alosco ML, Daneshvar DH, et al. Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology. Alzheimer’s Dement. 2021;17:1709–1724.
7. Stern RA, Adler CH, Chen K, et al. Tau positron-emission tomography in former national football league players. N Engl J Med. 2019; 380(18):1716–1725.
8. Lin A, Charney M, Shenton ME, Koerte IK. Chapter 29 – Chronic traumatic encephalopathy: neuroimaging biomarkers. In: Hainline B and Stern RA, eds. Handbook of clinical neurology, Vol. 158. Elsevier; 2018:309–322.
9. Gaetz M. The multi-factorial origins of Chronic Traumatic Encephalopathy (CTE) symptomology in post-career athletes: The
11. Mantyh WG, Spina S, Lee A, et al. Tau positron emission tomographic findings in a former US football player with pathologically confirmed chronic traumatic encephalopathy. JAMA Neurol. 2020;77(4):517–521.
12. Barrio JR, Small GW, Wong K-P, et al. In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging. PNAS. 2015;112(36):E2039–E2047.
13. Mitsis EM, Riggio S, Kostakoglu L, et al. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: Studies of a retired NFL player and of a man with FTD and a severe head injury. Transl Psychiatry. 2014;4(9):e441–e441.
14. Dickstein DL, Pullman MY, Fernandez C, et al. Radiosynthesis of N-(11C) methyl, [11C]-l-deprenyl as potential PET radioligands for imaging of carboxamide-3 (PK 11195): A new ligand for peripheral benzodiazepine receptor binding. J Nucl Med. 1984;25(10):985–991.
15. Coughlin JM, Wang Y, Munro CA, et al. Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. Neurobiol Dis. 2015;74:58–65.
16. Jain P, Chaney AM, Carlson ML, Jackson IM, Rao A, James ML. Neuroinflammation PET imaging: Current opinion and future directions. J Nucl Med. 2020;61(8):1107–1112.
17. Laurell GL, Plavén-Sigry P, Jucaite A, et al. Nondisplaceable binding is a potential confounding factor in [11C]-PBR28 translocator protein PET studies. J Nucl Med. 2021;62(3):412–417.
18. Narayanaswami V, Dahl K, Bernard-Gauthier V, Josephson L, Cummyng P, Vasdev N. Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: Outlook beyond TSPO. Mol Imaging. 2018;17:1–25.
19. Janssen B, Vugs DJ, Windhorst AD, Mach RH. PET imaging of microglial activation beyond targeting TSPO. Molecules. 2018;23:2018–2021.
20. Cumming P, Vasdev N. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18(4):431–435.
21. Ekblom J, Jossan S, Oreläinen L, Walum E, Aquilinson SM. Reactive gliosis and monoamine oxidase B. In: Tipton KF, Youdim MBH, Barwell CJ, Callingham BA and Lyles GA, eds. Amine oxidases: Function and dysfunction. Journal of Neural Transmission. Springer Vienna; 1994:253–258.
22. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis. 2000;1502(1):139–144.
23. Carter SF, Scholl M, Almkvist O, et al. Evidence for astrocytosis in pro-dromal Alzheimer disease provided by [11C] deuterium-L-deprenyl: A multitracer PET paradigm combining [11C]-Pittsburgh compound B and [11F]-FDG. J Nucl Med. 2012;53(1):37–46.
24. Gulyás B, Pavlova E, Kása P, et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int. 2011;58(1):60–68.
25. Shoulson I. DATATOP: A decade of neuroprotective innovation. Ann Neurol. 1998;44:160–166.
26. Narayanaswami V, Drake LR, Brooks AF, et al. Classics in neuroimaging: Development of PET tracers for imaging monoamine oxidases. ACS Chem Neurosci. 2019;10(4):1867–1871.
27. Rusjan PM, Wilson AA, Miler L, et al. Kinetic modeling of the monoamine oxidase B radioligand [11C]SL25.1188 in human brain with high-resolution positron emission tomography. J Cereb Blood Flow Metab. 2014;34(5):883–889.
28. Vasdev N, Sadowski O, Garcia A, et al. Radiosynthesis of [11C] SL25.1188 via [11C] CO2 fixation for imaging monoamine oxidase B. J Labelled Compd Radiopharm. 2011;54(10):678–680.
29. Wilson AA, Garcia A, Parkes J, et al. Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol. 2008;35(3):305–314.
30. Rusjan PM, Wilson AA, Bloomfield PM, et al. Quantitation of translocator protein binding in human brain with the Novel Radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab. 2011;31(8):1807–1816.
31. Narayanaswami V, Tong J, Schifani C, Bloomfield PM, Dahl K, Vasdev N. Preclinical evaluation of TSPO and MAO-B PET radiotracers in an LPS model of neuroinflammation. PET Clin. 2021;16(2):233–247.
32. Bernard-Gauthier V, Massine AV, Knight A, et al. Structural basis for achieving GSK-3β inhibition with high potency, selectivity, and brain exposure for positron emission tomography imaging and drug discovery. J Med Chem. 2019;62(21):9600–9617.
33. Patel S, Knight A, Krause S, et al. Preclinical in vitro and in vivo characterization of synthetic vesicle 2A-targeting compounds amenable to F-18 labeling as potential PET radioligands for imaging of synapse integrity. Mol Imaging Biol. 2019;22(4):832–841.
34. Owen DR, Howell OW, Tang S-P, et al. Two binding sites for [3H] PBR28 in human brain: Implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010;30(9):1608–1618.
35. Saura J, Kettler R, Da Prada M, Richards JG. Quantitative enzyme radiouautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: BRAIN COMMUNICATIONS 2022: Page 11 of 12 | 11
Localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. *J Neurosci*. 1992;12(5):1977–1999.

49. Janssen B, Vugts DJ, Wilkinson SM, et al. Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. *Sci Rep*. 2018;8(1):1–10.

50. Horti AG, Naik R, Foss CA, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). *PNAS*. 2019;116(5):1686–1691.

51. Knight AC, Varlow C, Zi T, et al. In vitro evaluation of [3H]CPPC as a tool radioligand for CSF1R. *ACS Chem Neurosci*. 2021;12(6):998–1006.

52. Mahar I, Alosco ML, McKee AC. Psychiatric phenotypes in chronic traumatic encephalopathy. *Neurosci Biobehav Rev*. 2017;83:622–630.

53. Batarseh A, Papadopoulos V. Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. *Mol Cell Endocrinol*. 2010;327(1–2):1–12.

54. Nutma E, Ceyzériat K, Amor S, et al. Cellular sources of TSPO expression in healthy and diseased brain. *Eur J Nucl Med Mol Imaging*. 2021;49:146–163.

55. Beckers L, Ory D, Geric I, et al. Increased Expression of Translocator Protein (TSPO) marks pro-inflammatory microglia but does not predict neurodegeneration. *Mol Imaging Biol*. 2018;20(1):94–102.

56. Owen DR, Narayan N, Wells L, et al. Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. *J Cereb Blood Flow Metab*. 2017;37(8):2679–2690.

57. Narayan N, Mandhair H, Smyth E, et al. The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory ‘M1’ human macrophages. *PLoS ONE*. 2017;12(10):e0185767.

58. Betlazar C, Harrison-Brown M, Middleton RJ, Banati R, Liu G-J. Cellular sources and regional variations in the expression of the neuroinflammatory marker translocator protein (TSPO) in the normal brain. *Int J Mol Sci*. 2018;19(9):2707.

59. Vicente-Rodríguez M, Singh N, Turkheimer F, et al. Resolving the cellular specificity of TSPO imaging in a rat model of peripherally-induced neuroinflammation. *Brain Behav Immun*. 2021;96:154–167.

60. Chancellor KB, Chancellor SE, Duke-Cohan JE, et al. Altered oligodendroglia and astroglia in chronic traumatic encephalopathy. *Acta Neuropathol*. 2021;142(2):295–321.

61. Ekhom J, Jossan SS, Bergström M, Oreland L, Walum E, Aquilinson S-M. Monoamine oxidase-B in astrocytes. *Glia*. 1993;8(2):122–132.

62. Cawshaw AA, Robertson NP. The role of TSPO PET in assessing neuroinflammation. *J Neurol*. 2017;264(8):1825–1827.

63. Notter T, Schalbether SM, Clifton NE, et al. Neuronal activity increases translocator protein (TSPO) levels. *Mol Psychiatry*. 2021;26:2025–2037.